drugset / Trial / NCT05689359

Evaluation of Hydroxychloroquine to Prevent CIPN

NCT05689359

Phase 2 Withdrawn University of Arizona
NaSingle-groupOpen-labelTreatment

Summary

The study is being done to research if hydroxychloroquine can prevent chemotherapy induced peripheral neuropathy. Certain chemotherapy drugs, like paclitaxel, are known to cause neuropathy which can impact quality of life. Currently, there are no options for preventing peripheral neuropathy. In addition, there are no useful methods to assess peripheral nerve damage. This study will also explore using a study MRI of patients' feet prior to starting chemotherapy and after they have completed chemotherapy to see if there is any difference in their nerve structure.

Timeline

Start
2024-06
Primary completion
2025-02-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Hydroxychloroquine Small molecule 600 mg Oral